TRAM Snapshot of App at Pub for Oppostn

AREXVY

GlaxoSmithKline Biologicals SA

TRAM Snapshot of App at Pub for Oppostn

Trademark Snap Shot Publication Stylesheet
(Table presents the data on Publication Approval)

OVERVIEW

SERIAL NUMBER 97052261 FILING DATE 09/29/2021
REG NUMBER 0000000 REG DATE N/A
REGISTER PRINCIPAL MARK TYPE TRADEMARK
INTL REG # N/A INTL REG DATE N/A
TM ATTORNEY CORDOVA, RAUL
L.O. ASSIGNED 114

PUB INFORMATION

RUN DATE 07/26/2022
PUB DATE 08/30/2022
STATUS 681-PUBLICATION/ISSUE REVIEW COMPLETE
STATUS DATE 07/25/2022
LITERAL MARK ELEMENT AREXVY

DATE ABANDONED N/A DATE CANCELLED N/A
SECTION 2F NO SECTION 2F IN PART NO
SECTION 8 NO SECTION 8 IN PART NO
SECTION 15 NO REPUB 12C N/A
RENEWAL FILED NO RENEWAL DATE N/A
DATE AMEND REG N/A


FILING BASIS

FILED BASIS CURRENT BASIS AMENDED BASIS
1 (a) NO 1 (a) NO 1 (a) NO
1 (b) YES 1 (b) NO 1 (b) NO
44D YES 44D NO 44D NO
44E NO 44E YES 44E NO
66A NO 66A NO

NO BASIS NO NO BASIS NO


MARK DATA

STANDARD CHARACTER MARK YES
LITERAL MARK ELEMENT AREXVY
MARK DRAWING CODE 4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG NO

CURRENT OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME GlaxoSmithKline Biologicals SA
ADDRESS Rue de l'Institut 89
Rixensart, B-1330
ENTITY 99-private company limited by shares (prc)
CITIZENSHIP Belgium

GOODS AND SERVICES

INTERNATIONAL CLASS 005
          DESCRIPTION TEXT Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 005 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION NO

FOREIGN INFORMATION

PRIORITY CLAIMED SEC. 44(D) ON United Kingdom
APPLICATION NO. 3662314
APPLICATION FILING DATE 06/30/2021
FOREIGN REG NO. N/A
FOREIGN REG DATE N/A
FOREIGN RNWL NUM N/A
DATE OF FOREIGN RNWL N/A
FOREIGN EXPIRATION N/A
FOREIGN RNWL EXPIRATION N/A
PRIORITY CLAIMED N/A
APPLICATION NO. N/A
APPLICATION FILING DATE N/A
FOREIGN REG NO. 018567660
FOREIGN REG DATE 02/10/2022
FOREIGN RNWL NUM N/A
DATE OF FOREIGN RNWL N/A
FOREIGN EXPIRATION 09/29/2031
FOREIGN RNWL EXPIRATION N/A

PROSECUTION HISTORY

DATE ENT CD ENT TYPE DESCRIPTION ENT NUM
07/23/2022 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER 007
07/22/2022 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED 006
07/22/2022 ALIE A ASSIGNED TO LIE 005
07/05/2022 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED 004
06/29/2022 DOCK D ASSIGNED TO EXAMINER 003
10/27/2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM 002
10/02/2021 NWAP I NEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY Christopher M. Hanes
CORRESPONDENCE ADDRESS Christopher M. Hanes
GSK
5 MOORE DRIVE
5.5A, LBP
RESEARCH TRIANGLE PARK, NC 27709
DOMESTIC REPRESENTATIVE NONE

TRAM Snapshot of App at Pub for Oppostn [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed